SIRPant Immunotherapeutics, Inc.
February 26, 2024
Gene/Cell Therapy
SIRPant Immunotherapeutics, Inc., a clinical stage company, programs the cells that drive immunity – macrophages – to mobilize effective polyclonal anti-cancer immune responses, providing a novel multipronged approach to combat aggressive tumors.
)
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}